only open flap debridement

PreclinicalSmall molecule

KKafrelsheikh University

only open flap debridement is one of 3 small molecule programs targeting Nanoparticle. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NanoparticleActive, not recruiting

NanoparticlePreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Nanoparticle

#DrugCompanyPhaseTrials

Feraheme

SStanford University

Preclinical

1 2

only open flap debridement

KKafrelsheikh University

Preclinical

1 3

Ferumoxtran-10

MM.D. Anderson Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nanoparticle1 trial

Efficacy of Camel Whey Protein and Camel Whey Protein Nanoparticles for Treating Intra-bony Periodontal Defects

Active, not recruiting·KKafrelsheikh University·N/A·NCT07358104·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for only open flap debridement. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — only open flap debridement compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for only open flap debridement. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kafrelsheikh University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKafrelsheikh University

only open flap debridement

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nanoparticle1 trial

References

Drug Info

Quick Facts

Related News